| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash (used in) provided by investing activities | -8,695 | 19,974 |
| Proceeds from issuance of shares of common stock under employee stock purchase plan | 46 | 46 |
| Proceed from borrowings under loan and security agreement | 0 | 0 |
| Proceeds from sale of shares of common stock, less issuance costs | 92,490 | 5,585 |
| Net cash provided by financing activities | 92,536 | 5,631 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 210 | 211 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 13,960 | -16,453 |
| Cash and cash equivalents at beginning of period | 56,475 | - |
| Cash and cash equivalents at end of period | 70,435 | - |
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)